Royalty Pharma Plc Stock Price, News & Analysis

Royalty Pharma (RPRX) announced it will report its Q4 and full year 2022 financial results on February 15, 2023, before the U.S. markets open. The company will host a conference call at 8:00 a.m. ET to discuss the results. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation across the industry, supporting numerous therapies through its extensive portfolio of royalties from over 35 commercial products, such as Vertex’s Trikafta and Biogen’s Tysabri. For further details, visit their Investors page.

Royalty Pharma (RPRX) has reported a strong operational performance for 2022, forecasting Net cash provided by operating activities of approximately $2.14 billion to $2.15 billion and Adjusted Cash Receipts of $2.785 billion to $2.79 billion, marking a 31% year-over-year growth. The company has achieved significant capital deployment, announcing $10 billion in transactions since 2020, projected to contribute $1 billion to future receipts. Management emphasizes resilience amid revenue declines in key areas, positioning for innovation and growth.

Royalty Pharma (RPRX) announced its acquisition of an interest in SPINRAZA® and pelacarsen royalties from Ionis Pharmaceuticals. The deal totals up to $1.125 billion, including a $500 million upfront payment and up to $625 million in milestone payments. Ionis retains a majority of the royalties and milestone payments for pelacarsen, expected to advance its late-stage programs and innovative pipeline. This partnership aims to enhance the commercial readiness of Ionis’s therapies targeting spinal muscular atrophy and cardiovascular diseases.

Ionis Pharmaceuticals has announced a significant royalty agreement with Royalty Pharma, involving an upfront payment of $500 million and potential milestones of up to $625 million. This deal allows Royalty Pharma to acquire an interest in Ionis' royalties from SPINRAZA and pelacarsen, while Ionis retains the majority of royalties and milestone payments from Novartis. The investment aims to bolster Ionis' late-stage programs and innovative genetic medicines pipeline, highlighting confidence in the commercial potential of both therapies.

Royalty Pharma plc (Nasdaq: RPRX) has declared a quarterly dividend of $0.20 per Class A share for the first quarter of 2023, marking a 5.3% increase from the previous quarter. The dividend will be paid on March 15, 2023, to shareholders of record as of February 16, 2023. CEO Pablo Legorreta emphasized the company's commitment to returning capital to shareholders while maintaining financial flexibility for future innovations, noting strong demand for capital in the biopharma sector.

Royalty Pharma, listed on Nasdaq as RPRX, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET. The presentation can be accessed via the company's Events page and will be archived for at least 30 days. Founded in 1996, Royalty Pharma is a leader in biopharmaceutical royalties, funding innovation through collaborations with various biopharmaceutical entities. Its portfolio includes royalties from over 35 commercial products.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a $25 million milestone payment from Amgen (NASDAQ: AMGN) triggered by the enrollment of the first subject in Amgen's Phase 3 trial of olpasiran. Arrowhead is also in line to receive up to $535 million in additional milestone payments from Amgen and Royalty Pharma (NASDAQ: RPRX). The olpasiran therapy targets lipoprotein(a) to reduce cardiovascular disease risk. This milestone represents significant progress for Arrowhead, being the second TRiM-enabled candidate to enter Phase 3 trials, with more projected to follow in the coming year.

Royalty Pharma plc (Nasdaq: RPRX) has announced key promotions within its senior leadership team effective January 1, 2023. Sara Klymkowsky and Brienne Kugler are promoted to Senior Vice President, Research & Investments, recognized for their significant contributions to major transactions since they joined the company in 2012 and 2014, respectively. Alessandra Sassun is appointed Senior Vice President, Head of Human Capital, bringing experience in human resources. CEO Pablo Legorreta expressed confidence that this strengthened leadership will enhance Royalty Pharma's mission in life sciences innovation and stakeholder value.

Royalty Pharma plc (Nasdaq: RPRX) is set to join the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022, at 10:30 a.m. ET. Investors can access the live webcast via Royalty Pharma’s “Events” page, where it will be archived for at least 30 days.

Royalty Pharma, founded in 1996, specializes in acquiring biopharmaceutical royalties. The company collaborates with various innovators across the biopharmaceutical sector and currently holds royalties for over 35 commercial products, enhancing the funding of innovation within the industry.